This white paper assesses India’s readiness as a global hub for lung cancer clinical trials. It highlights the country’s large patient population, expanding biomarker testing, and regulatory reforms under the New Drugs and Clinical Trials Rules. The report maps trial-ready sites, investigator expertise, and infrastructure improvements supporting complex oncology studies. It also reviews global NSCLC and SCLC pipeline activity to contextualize India’s growing role. The paper concludes that India is well positioned to accelerate lung cancer research through integrated global–local trial execution.

Join for free to read